Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Biogen's profit margin for the twelve months ending Sep 30, 2026 was 3.4%. For fiscal 2025 it was 13.1%, against 16.9% the year before. The highest annual figure on record is 41.0% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.1% | −3.8 |
| FY2024 | Dec 31, 2024 | 16.9% | +5.1 |
| FY2023 | Dec 31, 2023 | 11.8% | −18.1 |
| FY2022 | Dec 31, 2022 | 29.9% | +15.8 |
| FY2021 | Dec 31, 2021 | 14.2% | −15.6 |
| FY2020 | Dec 31, 2020 | 29.8% | −11.2 |
| FY2019 | Dec 31, 2019 | 41.0% | +8.0 |
| FY2018 | Dec 31, 2018 | 32.9% | +12.2 |
| FY2017 | Dec 31, 2017 | 20.7% | −11.7 |
| FY2016 | Dec 31, 2016 | 32.3% | −0.6 |
| FY2015 | Dec 31, 2015 | 33.0% | +2.7 |
| FY2014 | Dec 31, 2014 | 30.2% | +3.4 |
| FY2013 | Dec 31, 2013 | 26.9% | +1.8 |
| FY2012 | Dec 31, 2012 | 25.0% | +0.6 |
| FY2011 | Dec 31, 2011 | 24.5% | +3.1 |
| FY2010 | Dec 31, 2010 | 21.3% | −0.8 |
| FY2009 | Dec 31, 2009 | 22.2% | +3.0 |
| FY2008 | Dec 31, 2008 | 19.1% | −1.0 |
| FY2007 | Dec 31, 2007 | 20.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -0.7% | −19.1 |
| Q2 FY2026 | Jun 30, 2026 | 3.6% | −20.4 |
| Q1 FY2026 | Mar 31, 2026 | 12.9% | +3.0 |
| Q4 FY2025 | Dec 31, 2025 | -2.1% | −13.0 |
| Q3 FY2025 | Sep 30, 2025 | 18.4% | +2.6 |
| Q2 FY2025 | Jun 30, 2025 | 24.0% | +0.3 |
| Q1 FY2025 | Mar 31, 2025 | 9.9% | −7.3 |
| Q4 FY2024 | Dec 31, 2024 | 10.9% | +0.4 |
| Q3 FY2024 | Sep 30, 2024 | 15.8% | +18.4 |
| Q2 FY2024 | Jun 30, 2024 | 23.7% | −0.4 |
| Q1 FY2024 | Mar 31, 2024 | 17.2% | +1.4 |
| Q4 FY2023 | Dec 31, 2023 | 10.5% | −11.2 |
| Q3 FY2023 | Sep 30, 2023 | -2.7% | −47.9 |
| Q2 FY2023 | Jun 30, 2023 | 24.1% | −16.8 |
| Q1 FY2023 | Mar 31, 2023 | 15.7% | +3.7 |
| Q4 FY2022 | Dec 31, 2022 | 21.6% | +8.2 |
| Q3 FY2022 | Sep 30, 2022 | 45.2% | +33.4 |
| Q2 FY2022 | Jun 30, 2022 | 40.9% | +24.7 |
| Q1 FY2022 | Mar 31, 2022 | 12.0% | −3.2 |
| Q4 FY2021 | Dec 31, 2021 | 13.5% | +0.9 |
| Q3 FY2021 | Sep 30, 2021 | 11.8% | −8.9 |
| Q2 FY2021 | Jun 30, 2021 | 16.2% | −25.7 |
| Q1 FY2021 | Mar 31, 2021 | 15.2% | −24.4 |
| Q4 FY2020 | Dec 31, 2020 | 12.5% | −26.7 |
| Q3 FY2020 | Sep 30, 2020 | 20.8% | −22.2 |
| Q2 FY2020 | Jun 30, 2020 | 41.9% | +0.6 |
| Q1 FY2020 | Mar 31, 2020 | 39.6% | −0.8 |
| Q4 FY2019 | Dec 31, 2019 | 39.2% | +12.4 |
| Q3 FY2019 | Sep 30, 2019 | 42.9% | +0.9 |
| Q2 FY2019 | Jun 30, 2019 | 41.3% | +15.5 |
| Q1 FY2019 | Mar 31, 2019 | 40.4% | +2.9 |
| Q4 FY2018 | Dec 31, 2018 | 26.8% | +35.8 |
| Q3 FY2018 | Sep 30, 2018 | 42.0% | +2.2 |
| Q2 FY2018 | Jun 30, 2018 | 25.8% | −2.2 |
| Q1 FY2018 | Mar 31, 2018 | 37.5% | +10.9 |
| Q4 FY2017 | Dec 31, 2017 | -9.0% | −31.6 |
| Q3 FY2017 | Sep 30, 2017 | 39.8% | – |
| Q2 FY2017 | Jun 30, 2017 | 28.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 26.6% | – |
| Q4 FY2016 | Dec 31, 2016 | 22.6% | – |
See a number that looks wrong?